Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.66 Insider Own42.89% Shs Outstand94.84M Perf Week-1.27%
Market Cap1.06B Forward P/E- EPS next Y-1.77 Insider Trans-0.10% Shs Float55.72M Perf Month32.72%
Income-158.06M PEG- EPS next Q-0.49 Inst Own36.55% Short Float2.86% Perf Quarter83.61%
Sales0.00M P/S- EPS this Y29.61% Inst Trans0.06% Short Ratio4.05 Perf Half Y53.31%
Book/sh2.66 P/B4.09 EPS next Y-8.61% ROA-36.90% Short Interest1.59M Perf Year210.57%
Cash/sh2.88 P/C3.77 EPS next 5Y- ROE-49.99% 52W Range3.03 - 11.95 Perf YTD36.56%
Dividend Est.- P/FCF- EPS past 5Y- ROI-46.16% 52W High-9.04% Beta1.37
Dividend TTM- Quick Ratio9.51 Sales past 5Y0.00% Gross Margin- 52W Low258.75% ATR (14)0.78
Dividend Ex-Date- Current Ratio9.51 EPS Y/Y TTM34.27% Oper. Margin0.00% RSI (14)60.89 Volatility7.63% 8.07%
Employees124 Debt/Eq0.32 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price13.00
Option/ShortYes / Yes LT Debt/Eq0.32 EPS Q/Q29.79% Payout- Rel Volume0.66 Prev Close10.51
Sales Surprise- EPS Surprise23.06% Sales Q/Q- EarningsNov 13 AMC Avg Volume393.09K Price10.87
SMA2011.65% SMA5027.68% SMA20057.92% Trades Volume260,983 Change3.43%
Date Action Analyst Rating Change Price Target Change
Nov-15-23Upgrade Jefferies Hold → Buy $4 → $11
Oct-26-23Upgrade Morgan Stanley Underweight → Equal-Weight $4 → $8
Jun-21-23Initiated Evercore ISI Outperform
Jun-12-23Initiated Guggenheim Buy $9
Mar-17-23Initiated SVB Securities Outperform $6
Aug-12-22Downgrade Morgan Stanley Overweight → Underweight $10 → $5
Jun-17-22Initiated BMO Capital Markets Outperform $19
Jun-03-22Downgrade Jefferies Buy → Hold $37 → $4
Feb-11-22Initiated Goldman Neutral $12
Feb-22-24 08:00AM
Feb-09-24 07:00AM
Jan-22-24 08:00AM
Dec-13-23 08:00AM
Dec-10-23 12:05PM
09:55AM Loading…
Dec-05-23 09:55AM
Nov-27-23 04:15PM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:05PM
Nov-02-23 09:09AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-25-23 08:00AM
Oct-03-23 08:00AM
10:51AM Loading…
Sep-04-23 10:51AM
Aug-31-23 08:00AM
Aug-23-23 05:08PM
Aug-14-23 07:00AM
Jul-10-23 08:00AM
May-24-23 08:00AM
May-22-23 07:00AM
May-12-23 07:00AM
Apr-27-23 12:07PM
Mar-30-23 07:00AM
Mar-27-23 08:00AM
Mar-23-23 04:30PM
Mar-01-23 08:00AM
Feb-06-23 08:00AM
08:00AM Loading…
Feb-02-23 08:00AM
Jan-26-23 09:08AM
Dec-10-22 03:30PM
Nov-30-22 08:00AM
Nov-18-22 10:29AM
Nov-10-22 07:00AM
Nov-03-22 09:04AM
Oct-31-22 08:00AM
Sep-20-22 08:33AM
Sep-14-22 09:00AM
Sep-12-22 07:00AM
Aug-29-22 08:00AM
Aug-10-22 08:37AM
Jul-29-22 05:00AM
Jul-25-22 08:00AM
Jul-01-22 08:40AM
Jun-23-22 09:55AM
Jun-17-22 02:35PM
Jun-11-22 10:06AM
Jun-06-22 08:00AM
Jun-05-22 07:00AM
Jun-03-22 08:29AM
Jun-02-22 06:29AM
May-16-22 07:00AM
Mar-30-22 04:01PM
Mar-23-22 04:30PM
Mar-07-22 07:30AM
Feb-24-22 07:30AM
Feb-17-22 02:38AM
Jan-01-22 07:33AM
Dec-21-21 06:38PM
Dec-14-21 07:30AM
Dec-13-21 04:15PM
Dec-06-21 05:00PM
Nov-24-21 06:59AM
Nov-15-21 07:00AM
Nov-10-21 04:45PM
Nov-01-21 07:29PM
Oct-18-21 08:00AM
Oct-05-21 08:00AM
Oct-04-21 08:00AM
Sep-29-21 08:47AM
Sep-09-21 12:01PM
Sep-01-21 04:15PM
Aug-16-21 07:00AM
Jul-14-21 08:06AM
Jun-07-21 04:15PM
Jun-04-21 04:15PM
May-27-21 10:49PM
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rotman HarrisSVP Regulatory AffairsFeb 01Sale8.104,26734,57462,625Feb 02 05:03 PM
Rotman HarrisSVP Regulatory AffairsSep 20Option Exercise4.3737,484163,68870,984Sep 22 04:47 PM
Rotman HarrisSVP Regulatory AffairsSep 20Sale6.2937,484235,68833,500Sep 22 04:47 PM
YVER ANTOINEEVP & Chairman of DevelopmentJun 01Sale4.456,50028,949783,066Jun 02 05:01 PM
Bush Tia LChief Quality OfficerMay 24Sale4.488,00035,8650May 26 05:01 PM
YVER ANTOINEEVP & Chairman of DevelopmentMay 01Sale4.426,80030,083789,566May 02 05:01 PM